Phase 3, placebo-controlled
Topic / Pathology
- SLA
- Phase 3
Objectives
The objective is to compare the efficacy and safety of masitinib in combination with riluzole versus matched placebo in combination with riluzole for the treatment of Amyotrophic Lateral Sclerosis (ALS).
Find out more : https://clinicaltrials.gov/study/NCT03127267
Sponsor
AB Science
Investigator
National coordinator : Pr Philippe Corcia
Status
Suspended recruitment
